Agenda

February 28, 2009

7:30AM	Breakfast and Registrations
8:25AM	Welcome and Introductions	Chandra P. Belani, MD
Multimodality Therapy and Adjuvant Therapy Session Chair: Chandra P. Belani, MD
8:30AM	Novel Agents in Combination with Radiation Therapy for Lung Cancer	Walter Curran, MD
9:00AM	Management of Stage III Disease: Multimodality Therapy for Lung Cancer	Hak Choy, MD
9:30AM	Small Cell Lung Cancer: Novel Agents and Recent Advances	Ronald Natale, MD
10:00AM	Panel Discussion
10:20AM	BREAK
Targeting VEGF and EGFR Receptors in Lung Cancer Session Chair: Suresh Ramalingam, MD
10:30AM	Bevacizumab: Implications of Recent data in Non-Small-Cell Lung Cancer	Ronald Natale, MD
11:00AM	Small Molecule VEGF Receptor Tyrosine Kinase Inhibitors and Multikinase Inhibitors in the Treatment of Lung Cancer	Suresh Ramalingam, MD
11:30AM	Targeting EGFR-Monoclonal Antibodies and EGFR Tyrosine Kinase Inhibitors in Lung Cancer	Fred Hirsch, MD
12:00AM	Panel Discussion
12:20AM	LUNCH
State of the Art and Other Targeted Agents in Non-Small-Cell Lung Cancer SessionChair-Chandra P. Belani, MD
1:20AM	First-Line Chemotherapy Options for Advanced Lung Cancer	Chandra P. Belani, M
1:50AM	Second-line Chemotherapeutic Options for Lung Cancer	Ramaswamy Govindan, MD
2:20AM	Novel Agents in Lung Cancer: HDAC Inhibitors, Nab-Paclitaxel, Bortezomib, and Others	Fadlo Khuri, MD
2:50PM	Panel Discussion
3:10PM	Closing Remarks & Adjourn	Chandra P. Belani, M